

DAFTAR PUSTAKA

1. Badan Pusat Statistik. *Statistik Penduduk Lanjut Usia 2023*. Badan Pusat Statistik; 2023.
2. Ratnawati R, Nugrahenny D, Mattalitti GNM, et al. *Prinsip Dasar Kesehatan Lanjut Usia (Geriatric)*. Universitas Brawijaya Press; 2019.
3. Misrina T, Intannia D, Lingga HN, Rahmatullah SW. Potentially Inappropriate Medications (PIMs) dan Potentially Prescribing Omissions (PPOs) pada Pasien Geriatric Rawat Inap. *J Pharmascience*. 2023;10(2):296. doi:10.20527/jps.v10i2.17039
4. Julaiha S, Riyanto R, Pardilawati CY. Faktor yang Berhubungan dengan Kejadian Potentially Inappropriate Medication Berdasarkan Kriteria STOPP START pada Pasien Geriatric dengan Gangguan Kardiovaskuler. *J Kesehat Metro Sai Wawai*. 2021;14(2):156-167.
5. Julaiha S. Identifikasi Potentially Inappropriate Medications (PIMs) Berdasarkan Kriteria STOPP START pada Pasien Identification of Potentially Inappropriate Medications (PIMs) Using STOPP START Criteria in Hospitalized Geriatric Patients at Advent Hospital Bandar. *J Anal Kesehat*. 2018;7(1):657-665.
6. Nugroho W. *Keperawatan Gerontik Dan Geriatrik*. Edisi 3. EGC; 2012.
7. Ferry Efendi M. *Keperawatan Kesehatan Komunitas: Teori Dan Praktik Dalam Keperawatan*. Ferry Efendi; 2009.
8. Menteri Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 4 Tahun 2018 Tentang Kewajiban Rumah Sakit dan Kewajiban Pasien. Published online 2018.
9. Menteri Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 Tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019. Published online 2016.
10. Menteri Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2015 Tentang Penyelenggaraan Pelayanan kesehatan Lanjut Usia di Pusat Kesehatan Masyarakat. Published online 2015.
11. Ciccone CD. Chapter 6 - Geriatric Pharmacology. In: Avers D, Wong RA, eds. *Guccione's Geriatric Physical Therapy (Fourth Edition)*. Fourth Edi.

- Mosby; 2020:102-136. doi:<https://doi.org/10.1016/B978-0-323-60912-8.00006-3>
12. Sarbini D, Zulaikah S, Isnaeni FN. *Gizi Geriatri*. Muhammadiyah University Press; 2020.
 13. Kholifah SN. *Keperawatan Gerontik*. Kementerian Kesehatan RI; 2016.
 14. Mayangsari E, Lestari B, Soeharto S, et al. *Farmakologi Dasar*. Universitas Brawijaya Press; 2017.
 15. Syamsuni H. *Farmasetika Dasar & Hitungan Farmasi*. EGC; 2006.
 16. Joyce L. Kee ERH. *Farmakologi*. EGC; 1996.
 17. KeMenKes DJBK dan AKDKR. Pelayanan Farmasi (Tata Laksana Terapi Obat) Untuk Pasien Geriatri. Published online 2006:1-61.
 18. Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric Pharmacology: An Update. *Anesthesiol Clin*. 2019;37(3):475-492. doi:10.1016/j.anclin.2019.04.007
 19. Dr. apt. Dian Arsanti Palupi MF, apt. Heni Setyoningsih MF, apt. Rifda Naufa Lina MF, et al. *BUKU AJAR FARMAKOLOGI*. Feniks Muda Sejahtera; 2022.
 20. Akhtar S, Ramani R. Geriatric Pharmacology. *Anesthesiol Clin*. 2015;33(3):457-469. doi:10.1016/j.anclin.2015.05.004
 21. Kolo YMT. *POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) BERDASARKAN KRITERIA STOPP/START PASIEN STROKE HEMORAGIK PADA GERIATRI DI RSUD Dr.ISKAK KABUPATEN TULUNGAGUNG PERIODE JULI - DESEMBER 2017*. STIKES Karya Putra Bangsa Tulungagung; 2018.
 22. Huang AR, Mallet L. *Medication-Related Falls in Older People: Causative Factors and Management Strategies*. Springer International Publishing; 2016.
 23. Hukins D, Macleod U, Boland JW. Identifying potentially inappropriate prescribing in older people with dementia: a systematic review. *Eur J Clin Pharmacol*. 2019;75(4):467-481. doi:10.1007/s00228-018-02612-x
 24. Gatchel RJ, Schultz IZ, Ray CT. *Handbook of Rehabilitation in Older Adults*. Springer International Publishing; 2019.

25. Fahrni ML, Azmy MT, Usir E, Aziz NA, Hassan Y. Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study. *PLoS One*. 2019;14(7):1-20. doi:10.1371/journal.pone.0219898
26. Zulkarnaini A, Martini RD. Gambaran Polifarmasi Pasien Geriatri Dibeberapa Poliklinik RSUP Dr. M. Djamil Padang. *J Kesehat Andalas*. 2019;8(1S):1. doi:10.25077/jka.v8i1s.916
27. Ryan C, O'Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. *Br J Clin Pharmacol*. 2009;68(6):936-947. doi:10.1111/j.1365-2125.2009.03531.x
28. Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. *Arch Intern Med*. 2011;171(11):1013-1019. doi:10.1001/archinternmed.2011.215
29. Keche YN, Gaikwad NR, Wasnik PN, Siddiqui S, Nagpure K, Dhaneria S. Usefulness of STOPP/START criteria and Beers criteria for prescribing in geriatric patients in a tertiary health care center, Raipur, Central India. *J Fam Med Prim care*. 2022;11(11):7064-7071. doi:10.4103/jfmpe.jfmpe_733_22
30. Fitriah N. Analisis Penggunaan Obat Pada Pasien Geriatri Rawat Jalan Poli Jantung Rsd Dr. Soebandi Jember Dengan Metode Stopp Start. Published online 2017:1-43.
31. Yunita DR, Nurmainah N, Susanti R. DETEKSI PERESEPAN OBAT YANG TIDAK TEPAT PADA LANSIA RAWAT JALAN DI KLINIK PENYAKIT DALAM RSUD SULTAN SYARIF MOHAMAD ALKADRIE DENGAN MENGGUNAKAN METODE STOPP/START CRITERIA. *J Mhs Farm Fak Kedokt UNTAN*. 2022;6(1).
32. Fauziah H, Mulyana R, Martini RD. Polifarmasi Pada Pasien Geriatri. *Hum Care J*. 2020;5(3):804. doi:10.32883/hcj.v5i3.796
33. Hibattulwafi H, Ramadhan AM, Prabowo WC. Identifikasi Potensi Peresepan Obat Tidak Tepat pada Pasien Geriatri dengan Penyakit

- Kardiovaskular Berdasarkan Kriteria STOPP START di Salah Satu Rumah Sakit Balikpapan: Identification of Potentially Inappropriate Drug Prescribing in Geriatric Patients w. In: *Proceeding of Mulawarman Pharmaceuticals Conferences*. Vol 15. ; 2022:77-83.
34. Nursalam. *Konsep & Metode Keperawatan (Ed. 2)*. Salemba Medika; 2008.
 35. Sari Risal KJ. Analisis Luaran Pasien Malnutrisi yang Mendapat Terapi Gizi di RS Ibnu Sina Makassar Tahun 2015-2016. *UMI Med J*. 2019;4(1):1-11. doi:10.33096/umj.v4i1.47
 36. Darmojo RB, Martono HH. *Buku Ajar Geriatri (Ilmu Kesehatan Usia Lanjut)*. Balai Penerbit FKUI; 2019.
 37. Alkalah, Mubarak C. *Keperawatan Geronik*. Vol 19.; 2021.
 38. Kemenkes RI. *Profil Kesehatan Indonesia 2021*.; 2022.
 39. Kemenkes RI. *Pedoman Untuk Puskesmas Dalam Pemberdayaan Lanjut Usia*. Kementerian Kesehatan RI; 2018.
 40. Tan SJ, Cockcroft M, Page-Sharp M, et al. Population pharmacokinetic study of ceftriaxone in elderly patients, using cystatin C-based estimates of renal function to account for frailty. *Antimicrob Agents Chemother*. 2020;64(10):1-10. doi:10.1128/AAC.00874-20
 41. Hernández A, Romero L, Ruvalcaba J, López L. Usos terapéuticos del metronidazol y sus efectos secundarios: una actualización. *Eur Rev Med Pharmacol Sci*. 2019;23:397-401.
 42. AlMutairi H, O'Dwyer M, McCarron M, McCallion P, Henman MC. The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study. *Saudi Pharm J*. 2018;26(7):1012-1021. doi:10.1016/j.jsps.2018.05.009
 43. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. *Aging Dis*. 2018;9(1):143-150. doi:10.14336/AD.2017.0306
 44. Kusnia RI, Kusnia RI, Aryzki S, et al. Penggunaan obat antihipertensi pada pasien geriatri yang mengalami hipertensi rawat jalan di rsud ulin banjarasin. *J Ilm Farm Akad Farm*. 2024;7(2):80-93.
 45. Manirajan P, Sivanandy P. Drug Utilisation Review among Geriatric

- Patients with Noncommunicable Diseases in a Primary Care Setting in Malaysia. *Healthc.* 2023;11(12). doi:10.3390/healthcare11121665
46. Muriana R, Almeida M, Ramadhan AM. Identifikasi Potentially Inappropriate Medication (PIM's) Menggunakan Kriteria Beers dan STOPP pada Pasien Geriatri dengan Diagnosis Gastrointestinal Rawat Inap di RSUD Abdul Wahab Sjahranie Samarinda. *Proceeding Mulawarman Pharm Conf.* 2023;18:162-170. doi:10.25026/mpc.v18i1.721
 47. Liszka H, Zajac M, Gadek A. Pre-emptive analgesia with methylprednisolone and gabapentin in total knee arthroplasty in the elderly. *Sci Rep.* 2022;12(1):1-10. doi:10.1038/s41598-022-05423-4
 48. Ma F, Zhou X, Li Q, et al. Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design. *Curr Alzheimer Res.* 2019;16(7):622-632. doi:10.2174/1567205016666190725144629
 49. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: The process of deprescribing. *JAMA Intern Med.* 2015;175(5):827-834. doi:10.1001/jamainternmed.2015.0324
 50. Teh KJK, Puar HKT, How CH, Tan TKM. Deprescribing proton pump inhibitors. *Singapore Med J.* 2023;64(8):503-507. doi:10.4103/singaporemedj.SMJ-2021-445
 51. Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. *Chonnam Med J.* 2023;59(2):115. doi:10.4068/cmj.2023.59.2.115
 52. Linsky A, Simon SR, Bokhour B. Patient perceptions of proactive medication discontinuation. *Patient Educ Couns.* 2015;98(2):220-225. doi:10.1016/j.pec.2014.11.010
 53. Qiu J, Xu J, Pan X. Interpretation of 2021 ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. *Chinese Gen Pract.* 2021;24(36):4549-4554. doi:10.12114/j.issn.1007-9572.2021.02.055
 54. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet

- therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. *Circulation*. 2008;118(18):1894-1909. doi:10.1161/CIRCULATIONAHA.108.191087
55. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. *Am J Med*. 1999;106(5 B):13S-24S. doi:10.1016/S0002-9343(99)00113-8
 56. Grilli BA, Webb TG. Scope of Work: KDIGO Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) Update 2023 Background. *Strateg Sourc Public Sect*. Published online 2023:75-88. doi:10.4324/9781003267287-6
 57. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. *Arch Intern Med*. 2000;160(6):777-784. doi:10.1001/archinte.160.6.777
 58. Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. *Clin Cardiol*. 2016;39(2):111-118. doi:10.1002/clc.22502
 59. Palmer BF. Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System. *N Engl J Med*. 2004;351(6):585-592. doi:10.1056/nejmra035279
 60. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl*. 2013;3(1):1-150. doi:10.4324/9780203095744-31
 61. Brock C, Olesen SS, Olesen AE, Frøkjær JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: Pathophysiology and management. *Drugs*. 2012;72(14):1847-1865. doi:10.2165/11634970-000000000-00000
 62. American Geriatrics Society Beers Criteria®. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2019;67(4):674-694. doi:10.1111/jgs.15767
 63. Bozzo P, Koren G, Ito S. Health Canada advisory on domperidone: Should I

- avoid prescribing domperidone to women to increase milk production? *Can Fam Physician*. 2012;58(9):952-953.
64. Van Noord C, Dieleman JP, Van Herpen G, Verhamme K, Sturkenboom MCJM. Domperidone and ventricular arrhythmia or sudden cardiac death: A population-based case-control study in the Netherlands. *Drug Saf*. 2010;33(11):1003-1014. doi:10.2165/11536840-000000000-00000
 65. Gandelman J, Ureste P. Meta-analysis of the Impact of Nine Medication Classes on Falls in Elderly Persons. *Essent Rev Geriatr Psychiatry*. 2022;169(21):15-19. doi:10.1007/978-3-030-94960-0_3
 66. World Health Organization (WHO). *Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Middle-Income Countries: A WHO Practical Toolkit*. Vol 1.; 2019. doi:10.1093/jacamr/dlz072
 67. Dellit TH. Summary of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Infect Dis Clin Pract*. 2007;15(4):263-264. doi:10.1097/IPC.0b013e318068b1c0
 68. Broek RPG, Krielen P, Di Saverio S, et al. Bologna guidelines for diagnosis and management of adhesive small bowel obstruction (ASBO). *World J Emerg Surg*. 2018;13(1):13-24.
 69. O'mahony D, O'sullivan D, Byrne S, O'connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. *Age Ageing*. 2015;44(2):213-218. doi:10.1093/ageing/afu145
 70. Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. *Chest*. 2006;129(1 SUPPL.):238S-249S. doi:10.1378/chest.129.1_suppl.238S
 71. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task . Vol 71.;

2018. doi:10.1161/HYP.0000000000000066

72. Group TAO and C for the ACR, Coordinators TAO and, Antihypertensive T, Treatment L lowering. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. *JAMA J Am Med Assoc.* 2002;288(23):2981-2997.
73. Camaschella C. Iron-Deficiency Anemia. *N Engl j Med.* 2015;372:1832-1843. doi:10.1056/NEJMra1401038
74. Ickowicz E. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc.* 2009;57(8):1331-1346. doi:10.1111/j.1532-5415.2009.02376.x
75. American Diabetes Association. American Diabetes Association Releases 2023 Standards of Care in Diabetes to Guide Prevention, Diagnosis, and Treatment for People Living with Diabetes. *Clin Electroencephalogr.* 2023;13(3):136-136. doi:10.1177/155005948201300303
76. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J.* 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
77. Valderrama-Rios MC, Álvarez-Moreno CA, Cortes JA. Interventions to Improve Antibiotic Use in Hospitals with Different Levels of Complexity in Colombia: Findings from a Before-and-After Study and Suggestions for the Future. *Antibiotics.* 2023;12(5). doi:10.3390/antibiotics12050867
78. Elsayed NA, Aleppo G, Aroda VR, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023. *Diabetes Care.* 2023;46(January):S191-S202. doi:10.2337/dc23-S010
79. Brenner BM, Cooper ME, Zeeuw D de, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001 Sep 20;345(12):861-9. *N Eng J Med.* 2001;345(12):861-869.
80. Perazella MA. Pharmacology behind common drug nephrotoxicities. *Clin J Am Soc Nephrol.* 2018;13(12):1897-1908. doi:10.2215/CJN.00150118
81. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and

- management of gastroesophageal reflux disease. *Am J Gastroenterol*. 2013;108(3):308-328. doi:10.1038/ajg.2012.444
82. Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. *Gut Liver*. 2018;12(1):7-16. doi:10.5009/gnl16615
 83. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid*. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028
 84. Wiersinaga WM. *Myxedema and Coma (Severe Hypothyroidism)*.; 2018.
 85. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol*. 2011;185(5):1793-1803. doi:10.1016/j.juro.2011.01.074
 86. Elhilali MM. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. *Expert Opin Pharmacother*. 2006;7(5):583-596. doi:10.1517/14656566.7.5.583
 87. Argoff CE. Opioid-induced Constipation: A Review of Health-related Quality of Life, Patient Burden, Practical Clinical Considerations, and the Impact of Peripherally Acting μ -Opioid Receptor Antagonists. *Clin J Pain*. 2020;36(9):716-722. doi:10.1097/AJP.0000000000000852
 88. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017;136(6):e137-e161. doi:10.1161/CIR.0000000000000509
 89. McMurray JJ V, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. *Eur Heart J*. 2012;33(14):1787-1847. doi:10.1093/eurheartj/ehs104

90. Wołowiec Ł, Osiak-Gwiazdowska J, Jaśniak A, et al. Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors. *Front Pharmacol*. 2025;16(July):1-13. doi:10.3389/fphar.2025.1507812
91. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. *Lancet (London, England)*. 2007;370(9582):185-191. doi:10.1016/S0140-6736(07)61092-7
92. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. *Am J Med*. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8